Innovative Presentation by Glaukos Corporation
Glaukos Corporation (NYSE: GKOS), an advanced ophthalmic pharmaceutical and medical technology leader, is excited to announce its participation at the American Academy of Ophthalmology (AAO) annual meeting. The event is set to take place from October 18 to October 21, 2024. This annual meeting is renowned for being a premier venue for ophthalmic professionals to gather and discuss the latest advances and therapies in eye health.
Exhibitions and Symposia
This year, Glaukos will have a significant presence by showcasing its ground-breaking technologies at booth #2608. In addition to the exhibition, the company will sponsor an educational symposium titled “iDose TR: The Gateway to Interventional Glaucoma.” This symposium, slated for the morning of October 19, will feature a panel of esteemed experts in the field, including Dr. Ike Ahmed, Dr. John Berdahl, Dr. Nathan Radcliffe, Dr. Deborah Ristvedt, and Dr. Savak Teymoorian.
Highlighting Key Research
Attendees at the AAO will be presented with essential posters and presentations aimed at increasing understanding and fostering collaboration within the field. One of the critical highlights involves a poster by Dr. John Berdahl that discusses the effects of the Travoprost Intracameral Implant in patients who experienced previous failures with selective laser trabeculoplasty (SLT).
Another noteworthy presentation by Dr. Mohammed ElMallah focuses on the long-term therapeutic effects of the iDose TR, showcasing its ability to maintain adequate aqueous humor drug levels while effectively lowering intraocular pressure over a span of 24 months.
Additionally, Dr. Ali Salimi will discuss the decade-long outcomes from utilizing first-generation trabecular micro-bypass stents, contributing valuable insights into the intersection of surgical interventions and glaucoma management.
Corneal Health Presentations
In a continued effort to shed light on other aspects impacting eye health, Dr. Weijie Lin will present research targeting the risk factors associated with complications following corneal cross-linking treatments for keratoconus.
Engaging with the Ophthalmic Community
The AAO Annual Meeting remains one of the largest gatherings in the ophthalmic sector, attracting physicians, medical personnel, and industry executives. Engaging in discussions at this meeting allows Glaukos and other attendees to contribute to the ongoing advancements in the treatment and management of eye diseases.
About Glaukos Corporation
Glaukos is dedicated to pioneering the development and commercialization of innovative therapies aimed at treating glaucoma, corneal diseases, and retinal disorders. With a commitment to enhancing patient care, Glaukos introduced Micro-Invasive Glaucoma Surgery (MIGS) and launched its inaugural MIGS device in 2012. More recently, the company has introduced iDose TR, an innovative solution designed for consistent glaucoma therapy through a long-lasting, intraocular delivery system.
The iDose TR not only represents a significant milestone for glaucoma treatment but also showcases Glaukos’s determination to redefine existing paradigms through its continued research and development efforts. Furthermore, Glaukos is recognized for its FDA-approved corneal cross-linking therapy, which utilizes a proprietary bio-activated formulation tailored for keratoconus— a rare condition affecting the cornea.
Innovative Technology in Action
iDose TR functions as a long-duration prostaglandin analog specially designed for direct intraocular administration, focusing on sustained release to effectively manage intraocular pressure in individuals facing open-angle glaucoma or ocular hypertension. Its innovative delivery mechanism enables continuous medication release, presenting a viable option for patients.
Client Safety and Efficacy
As with all medical interventions, safety remains a cornerstone of Glaukos’s approach. The iDose TR is contraindicated in individuals with known hypersensitivities or certain ocular conditions, and its use mandates a careful assessment by healthcare professionals. Regular monitoring is essential to ascertain appropriate placement and efficacy over time.
The Future of Eye Health
Glaukos is committed to advancing a robust pipeline of unique dropless technologies which are anticipated to profoundly enhance the management of chronic eye conditions. As the industry evolves, Glaukos aims to lead the way with therapies that prioritize patient outcomes and an improved quality of life.
Frequently Asked Questions
What is Glaukos Corporation known for?
Glaukos Corporation is renowned for developing innovative therapies for the management of glaucoma and other ocular conditions.
When is the AAO Annual Meeting?
The American Academy of Ophthalmology Annual Meeting is scheduled from October 18 to October 21, 2024.
What technologies will Glaukos present at the AAO meeting?
Glaukos will showcase technologies including the iDose TR and discuss various key research findings related to glaucoma treatment.
Who are the speakers at the educational symposium?
The symposium will feature distinguished speakers such as Dr. Ike Ahmed and Dr. John Berdahl, among others.
What is the focus of the symposium led by Glaukos?
The symposium is centered around interventional glaucoma treatments, particularly the iDose TR device.
